|
|
Article: Positive phase 2 results reported for Alista in premenopausal women with FSAD.
- Article from:
- Drug Week
- Article date:
- August 13, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 AUG 13 - (NewsRx.com & NewsRx.net) -- VIVUS, Inc. (VVUS) announced that data from a recently completed phase 2 clinical trial demonstrated that Alista significantly increased the percentage of satisfying sexual events in premenopausal women with female sexual arousal disorder (FSAD) when compared with placebo.
Sixty-four percent of Alista doses resulted in satisfying sexual events (p
This double-blind, randomized, placebo-controlled, crossover study evaluated the efficacy and safety of ALISTA for premenopausal women in the home setting. In this study, involving 6 different sites, 36 women received at least one dose each of the placebo and active drug.
...